Q32 Bio Inc. (QTTB)

USD 3.13

(-8.75%)

Market Cap (In USD)

38.12 Million

Revenue (In USD)

1.15 Million

Net Income (In USD)

-112.96 Million

Avg. Volume

124.05 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.02-53.79
PE
-
EPS
-
Beta Value
0.0
ISIN
US7469641051
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Jodie Pope Morrison
Employee Count
-
Website
-
Ipo Date
2018-03-28
Details
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.